Safi U Khan1, Mohammed Osman1, Muhammad U Khan1, Muhammad Shahzeb Khan2, Di Zhao3, Mamas A Mamas4, Nazir Savji5, Ahmad Al-Abdouh6, Rani K Hasan5, Erin D Michos7. 1. West Virginia University, Morgantown, West Virginia (S.U.K., M.O., M.U.K.). 2. John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois (M.S.K.). 3. Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (D.Z.). 4. Keele University, Stoke-on-Trent, United Kingdom, and Thomas Jefferson University, Philadelphia, Pennsylvania (M.A.M.). 5. Johns Hopkins School of Medicine, Baltimore, Maryland (N.S., R.K.H.). 6. Saint Agnes Hospital, Baltimore, Maryland (A.A.). 7. Johns Hopkins Bloomberg School of Public Health and Johns Hopkins School of Medicine, Baltimore, Maryland (E.D.M.).
Abstract
Background: The safety and effectiveness of dual therapy (direct oral anticoagulant [DOAC] plus P2Y12 inhibitor) versus triple therapy (vitamin K antagonist plus aspirin and P2Y12 inhibitor) in patients with nonvalvular atrial fibrillation (AF) after percutaneous coronary intervention (PCI) is unclear. Purpose: To examine the effects of dual versus triple therapy on bleeding and ischemic outcomes in adults with AF after PCI. Data Sources: Searches of PubMed, EMBASE, and the Cochrane Library (inception to 31 December 2019) and ClinicalTrials.gov (7 January 2020) without language restrictions; journal Web sites; and reference lists. Study Selection: Randomized controlled trials that compared the effects of dual versus triple therapy on bleeding, mortality, and ischemic events in adults with AF after PCI. Data Extraction: Two independent investigators abstracted data, assessed the quality of evidence, and rated the certainty of evidence. Data Synthesis: Four trials encompassing 7953 patients were selected. At the median follow-up of 1 year, high-certainty evidence showed that dual therapy was associated with reduced risk for major bleeding compared with triple therapy (risk difference [RD], -0.013 [95% CI, -0.025 to -0.002]). Low-certainty evidence showed inconclusive effects of dual versus triple therapy on risks for all-cause mortality (RD, 0.004 [CI, -0.010 to 0.017]), cardiovascular mortality (RD, 0.001 [CI, -0.011 to 0.013]), myocardial infarction (RD, 0.003 [CI, -0.010 to 0.017]), stent thrombosis (RD, 0.003 [CI, -0.005 to 0.010]), and stroke (RD, -0.003 [CI, -0.010 to 0.005]). The upper bounds of the CIs for these effects were compatible with possible increased risks with dual therapy. Limitation: Heterogeneity of study designs, dosages of DOACs, and types of P2Y12 inhibitors. Conclusion: In adults with AF after PCI, dual therapy reduces risk for bleeding compared with triple therapy, whereas its effects on risks for death and ischemic end points are still unclear. Primary Funding Source: None.
Background: The safety and effectiveness of dual therapy (direct oral anticoagulant [DOAC] plus P2Y12 inhibitor) versus triple therapy (vitamin K antagonist plus aspirin and P2Y12 inhibitor) in patients with nonvalvular atrial fibrillation (AF) after percutaneous coronary intervention (PCI) is unclear. Purpose: To examine the effects of dual versus triple therapy on bleeding and ischemic outcomes in adults with AF after PCI. Data Sources: Searches of PubMed, EMBASE, and the Cochrane Library (inception to 31 December 2019) and ClinicalTrials.gov (7 January 2020) without language restrictions; journal Web sites; and reference lists. Study Selection: Randomized controlled trials that compared the effects of dual versus triple therapy on bleeding, mortality, and ischemic events in adults with AF after PCI. Data Extraction: Two independent investigators abstracted data, assessed the quality of evidence, and rated the certainty of evidence. Data Synthesis: Four trials encompassing 7953 patients were selected. At the median follow-up of 1 year, high-certainty evidence showed that dual therapy was associated with reduced risk for major bleeding compared with triple therapy (risk difference [RD], -0.013 [95% CI, -0.025 to -0.002]). Low-certainty evidence showed inconclusive effects of dual versus triple therapy on risks for all-cause mortality (RD, 0.004 [CI, -0.010 to 0.017]), cardiovascular mortality (RD, 0.001 [CI, -0.011 to 0.013]), myocardial infarction (RD, 0.003 [CI, -0.010 to 0.017]), stent thrombosis (RD, 0.003 [CI, -0.005 to 0.010]), and stroke (RD, -0.003 [CI, -0.010 to 0.005]). The upper bounds of the CIs for these effects were compatible with possible increased risks with dual therapy. Limitation: Heterogeneity of study designs, dosages of DOACs, and types of P2Y12 inhibitors. Conclusion: In adults with AF after PCI, dual therapy reduces risk for bleeding compared with triple therapy, whereas its effects on risks for death and ischemic end points are still unclear. Primary Funding Source: None.
Authors: Jonathan A C Sterne; Jelena Savović; Matthew J Page; Roy G Elbers; Natalie S Blencowe; Isabelle Boutron; Christopher J Cates; Hung-Yuan Cheng; Mark S Corbett; Sandra M Eldridge; Jonathan R Emberson; Miguel A Hernán; Sally Hopewell; Asbjørn Hróbjartsson; Daniela R Junqueira; Peter Jüni; Jamie J Kirkham; Toby Lasserson; Tianjing Li; Alexandra McAleenan; Barnaby C Reeves; Sasha Shepperd; Ian Shrier; Lesley A Stewart; Kate Tilling; Ian R White; Penny F Whiting; Julian P T Higgins Journal: BMJ Date: 2019-08-28
Authors: Davide Capodanno; Roxana Mehran; Marco Valgimigli; Usman Baber; Stephan Windecker; Pascal Vranckx; George Dangas; Fabiana Rollini; Takeshi Kimura; Jean-Philippe Collet; C Michael Gibson; Philippe Gabriel Steg; Renato D Lopes; Hyeon-Cheol Gwon; Robert F Storey; Francesco Franchi; Deepak L Bhatt; Patrick W Serruys; Dominick J Angiolillo Journal: Nat Rev Cardiol Date: 2018-08 Impact factor: 32.419
Authors: Davide Capodanno; Kurt Huber; Roxana Mehran; Gregory Y H Lip; David P Faxon; Christopher B Granger; Pascal Vranckx; Renato D Lopes; Gilles Montalescot; Christopher P Cannon; Jurien Ten Berg; Bernard J Gersh; Deepak L Bhatt; Dominick J Angiolillo Journal: J Am Coll Cardiol Date: 2019-07-09 Impact factor: 24.094
Authors: Safi U Khan; Muhammad U Khan; Ali Raza Ghani; Ahmad N Lone; Adeel Arshad; Edo Kaluski Journal: Am J Cardiol Date: 2018-02-14 Impact factor: 2.778
Authors: Tracy Y Wang; Lee A Robinson; Fang-Shu Ou; Matthew T Roe; E Magnus Ohman; W Brian Gibler; Sidney C Smith; Eric D Peterson; Richard C Becker Journal: Am Heart J Date: 2007-10-25 Impact factor: 4.749
Authors: Pascal Vranckx; Marco Valgimigli; Peter Jüni; Christian Hamm; Philippe Gabriel Steg; Dik Heg; Gerrit Anne van Es; Eugene P McFadden; Yoshinobu Onuma; Cokky van Meijeren; Ply Chichareon; Edouard Benit; Helge Möllmann; Luc Janssens; Maurizio Ferrario; Aris Moschovitis; Aleksander Zurakowski; Marcello Dominici; Robert Jan Van Geuns; Kurt Huber; Ton Slagboom; Patrick W Serruys; Stephan Windecker Journal: Lancet Date: 2018-08-27 Impact factor: 79.321
Authors: Giuseppe Gargiulo; Andreas Goette; Jan Tijssen; Lars Eckardt; Thorsten Lewalter; Pascal Vranckx; Marco Valgimigli Journal: Eur Heart J Date: 2019-12-07 Impact factor: 29.983
Authors: Leonardo De Luca; Raffaella Mistrulli; Francesco Antonio Veneziano; Francesco Grigioni; Massimo Volpe; Francesco Musumeci; Domenico Gabrielli Journal: J Clin Med Date: 2022-01-20 Impact factor: 4.241
Authors: Johannes M Weller; Franziska Dorn; Julius N Meissner; Sebastian Stösser; Niklas M Beckonert; Julia Nordsiek; Christine Kindler; Christoph Riegler; Fee Keil; Gabor C Petzold; Felix J Bode Journal: Neurol Res Pract Date: 2022-09-12